Skip to NavigationSkip to content

AbbVie

Abbvie psoriatic arthritis drug approved for use in Scotland

NHS building

Abbvie’s RINVOQ (upadacitinib) drug, for the treatment of active psoriatic arthritis (PsA) in adults, has been approved for use in NHS Scotland by the Scottish Medicines Consortium.

AbbVie funds Mitokinin's Parkinson's research with option to buy

Image credit: AbbVie

AbbVie has landed an option to buy neurodegenerative disease-focused biotech Mitokinin following completion of investigational new drug (IND)-enabling studies on its lead PINK1 compound.

Based on technology discovered at University of California San Francisco by Mitokinin co-founders Nicholas Hertz and Kevan Shokat, Mitokinin moved into MBC BioLabs San Francisco in 2017 with series A funding from a syndicate led by Mission BioCapital.   

AbbVie's rheumatoid arthritis drug Rinvoq approved for NHS Scotland

The Scottish Medicines Consortium (SMC) has recommended AbbVie’s rheumatoid arthritis (RA) drug Rinvoq (upadacitinib) for use on the NHS in Scotland.

Upadacitinib, a janus kinase inhibitor (JAKi), is a once-daily oral therapy for people with previously treated severe active RA.

AbbVie's psoriatic arthritis and ankylosing spondylitis drug gets EU approval

The European Commission (EC) has approved AbbVie’s RINVOQTM (upadacitinib 15 mg), an oral, once-daily selective and reversible JAK inhibitor for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs).

RINVOQ may be used as a monotherapy or in combination with methotrexate. The drug is also indicated for the treatment of active ankylosing spondylitis (AS) in adult patients who have responded inadequately to conventional therapy.

AbbVie unveils new Phase 3 upadacitinib data in moderate to severe ulcerative colitis

AbbVie has announced data from the first of two Phase 3 studies investigating the efficacy of upadacitinib in treating moderate to severe ulcerative colitis in adult patients, showing that the therapy met its primary and secondary endpoints.

According to the Adapted Mayo Score, 26% of patients receiving AbbVie’s therapy achieved clinical remission after eight weeks of treatment, whereas just 5% of patients receiving placebo achieved the same. With that achievement, the therapy passed its main goal in the trial.

NICE recommends venetoclax combo, a non-chemo option for untreated chronic lymphocytic leukaemia

NICE has recommended venetoclax in combination with obinutuzumab under final draft guidance for the first-line treatment of untreated chronic lymphocytic leukaemia (CLL), providing access to a 12-month chemotherapy-free option to patients in England and Wales via the NHS.

CLL is the most common form of chronic leukaemia, accounting for around a third of all adult cases and with 3,157 new diagnoses of the condition in England in 2017. It’s estimated that more than 1,000 treatment-naïve CLL patients will be eligible to access the therapy through this decision.

FDA approves Venclexta combo in acute myeloid leukaemia, despite it missing main study goal

The FDA has given approval to AbbVie and Roche’s jointly-developed BCL-2 inhibitor Venclexta (venetoclax) in combination with azacitidine, decitabine, or low-dose cytarabine as a treatment for newly-diagnosed acute myeloid leukaemia (AML) in patients at least 75 years old, or who have comorbidities that make the use of intensive induction chemotherapy inappropriate.

AbbVie's Rinvoq smashes Phase 3 efficacy targets in atopic dermatits

AbbVie has lifted the curtain on data from the second Phase 3 trial investigating the efficacy of Rinvoq (upadacitinib) monotherapy in the treatment of moderate to severe atopic dermatitis in adults and adolescent patients eligible for systemic therapy, after the drug nailed its primary and secondary endpoints.

The drug was aiming to elicit a 75% improvement from baseline in patients on the Eczema Area Severity Index (EASI 75), as well as a validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD) score of 0/1 (clear or almost clear) after 16 weeks of treatmen

FDA rejects Allergan's Abicipar pegol for neovascular age-related macular degeneration over benefit/risk concerns

The FDA has moved to reject Allergan’s vascular endothelial growth factor (VEGF) factor A inhibitor, Abicipar pegol, as treatment for the eye condition known as neovascular age-related macular degeneration (nAMD).

The drug application was supported by data from two trials which showed the non-inferiority of Abicipar pegol to Genentech’s Lucentis (ranibizumab) in treatment-naïve (nAMD), with six or eight injections of the former proving as effective as 13 doses of the latter after 52 weeks.

AbbVie’s Venclexta plus azacitidine shows improved survival and remissions rates in leukaemia patients

U.S. Air Force photo by Heide Couch

AbbVie have announced positive results from its latest Phase 3 clinical trial where Venclexta plus azacitidine improved survival and remission rates in treatment-naïve acute myeloid leukaemia patients (AML).

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches